• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Potential Role of AI in HS Diagnosis

Author(s):

Merrick D. Elias, DO, FAAD,Hadar Avihai Lev-Tov, MD

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts in this video
3 experts in this video
Related Content
Navigating Challenges and Inspiring Advocacy: A Pre-Med Student's Journey With HS
December 5th 2024

Navigating Challenges and Inspiring Advocacy: A Pre-Med Student's Journey With HS

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology
June 25th 2020

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology

Study Reveals Potential Genetic Connection Between Hidradenitis Suppurativa and Increased Risk of CAD and Diabetes
November 26th 2024

Study Reveals Potential Genetic Connection Between Hidradenitis Suppurativa and Increased Risk of CAD and Diabetes

Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS
November 26th 2024

Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS

AI Chatbots Can Provide Support to Patients with Hidradenitis Suppurativa
November 20th 2024

AI Chatbots Can Provide Support to Patients with Hidradenitis Suppurativa

FDA Approves Bimekizumab for Adults with Moderate to Severe HS
November 20th 2024

FDA Approves Bimekizumab for Adults with Moderate to Severe HS

© 2024 MJH Life Sciences

All rights reserved.